Stockscreener 앱 받기
1.4073
2.27%
-0.0327
전일 마감가:
$1.44
열려 있는:
$1.45
하루 거래량:
14,276
Relative Volume:
0.05
시가총액:
$53.15M
수익:
-
순이익/손실:
$-8.82M
주가수익비율:
-4.691
EPS:
-0.3
순현금흐름:
$-18.01M
1주 성능:
-9.79%
1개월 성능:
-31.35%
6개월 성능:
+61.50%
1년 성능:
+26.78%
1일 변동 폭
$1.3966
$1.5135
1주일 범위
$1.19
$1.54
52주 변동 폭
$0.7301
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
명칭
Estrella Immunopharma Inc
전화
(510) 318-9098
주소
5858 HORTON STREET, SUITE 370, EMERYVILLE
ESLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.4073 | 54.38M | 0 | -8.82M | -18.01M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.03 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
815.08 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
415.22 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.24 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
171.16 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Is Estrella Immunopharma Inc. stock a good choice for value investorsTake Profit & Short-Term Swing Trade Alerts - ulpravda.ru
Published on: 2026-01-07 23:18:22 - ulpravda.ru
How interest rate cuts could boost Estrella Immunopharma Inc. stockSector Leadership Analysis & Small Capital Trading Growth - ulpravda.ru
Estrella Immunopharma Secures $8 Million in Funding to Advance Cancer Therapy Programs - citybuzz -
Estrella Immunopharma completes $8M direct offering financing - TipRanks
Estrella Immunopharma Signs Multiple Material Agreements - TradingView — Track All Markets
Estrella Immunopharma closes $8 million registered direct offering - Investing.com
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement - The AI Journal
Estrella Immunopharma closes $8 million registered direct offering By Investing.com - Investing.com India
Estrella Immunopharma raises $8 million through registered offering By Investing.com - Investing.com Nigeria
Estrella Immunopharma stock falls after announcing $8 million offering - Investing.com India
Estrella Immunopharma raises $8 million through registered offering - Investing.com
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - The AI Journal
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Grows By 28.5% - MarketBeat
Aug Levels: How Estrella Immunopharma Inc stock reacts to global recession fearsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - moha.gov.vn
Estrella Immunopharma (ESLAW) Stock Analysis Report | Financials & Insights - Benzinga
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma offers up to 2.5 mln shares for resale by selling stockholders - marketscreener.com
Estrella Immunopharma Files for Secondary Offering - marketscreener.com
Investment Review: How interest rate cuts could boost Estrella Immunopharma Inc. stock2025 AllTime Highs & Free Growth Oriented Trading Recommendations - Улправда
Why Estrella Immunopharma Inc. stock remains on buy listsVolume Spike & Free Technical Pattern Based Buy Signals - Улправда
Is Estrella Immunopharma Inc. stock affected by interest rate hikes - Улправда
Is Estrella Immunopharma Inc. stock a safe haven assetEarnings Recap Report & Accurate Buy Signal Alerts - Улправда
Insider Buy: Is Estrella Immunopharma Inc. stock a safe haven asset2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks - Улправда
Can Estrella Immunopharma Inc. stock sustain market leadershipJuly 2025 WrapUp & High Accuracy Swing Trade Signals - DonanımHaber
Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% HigherHere's Why - MarketBeat
Levels Update: How interest rate cuts could boost Estrella Immunopharma Inc. stockWeekly Stock Recap & Verified Swing Trading Watchlists - ulpravda.ru
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review - MSN
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Estrella Immunopharma (ESLA) Stock Analysis Report | Financials & Insights - Benzinga
Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com Nigeria
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView — Track All Markets
Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada
Estrella’s EB103 advances to Phase II after positive safety data - Investing.com
Estrella advances Starlight-1 trial into phase II following positive DSMB recommendation - marketscreener.com
Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Business Wire
Is Estrella Immunopharma Inc. stock a defensive play in 2025Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Here's Why We're Not Too Worried About Estrella Immunopharma's (NASDAQ:ESLA) Cash Burn Situation - Sahm
Estrella Immunopharma (NASDAQ:ESLA) Raised to “Hold” at Wall Street Zen - Defense World
Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen - MarketBeat
How Estrella Immunopharma Inc. stock benefits from global expansionInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-11-19 23:49:15 - newser.com
Is Estrella Immunopharma Inc. stock oversold or undervaluedStock Surge & Free High Accuracy Swing Entry Alerts - newser.com
What data driven models say about Estrella Immunopharma Inc.’s futureJuly 2025 Highlights & Capital Protection Trade Alerts - newser.com
Is now a turning point for Estrella Immunopharma Inc.July 2025 Chart Watch & Advanced Technical Analysis Signals - newser.com
Estrella Immunopharma Inc (ESLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.23%
자본화:
|
볼륨(24시간):